Phosphorylation-independent mTORC1 inhibition by the autophagy inducer Rottlerin

Cancer Letters

Volumn 360, Issue 1, 2015, Pages 17-27

  Torricelli, C ^a   Daveri, E ^a   Salvadori, S ^a   Valacchi, G ^b,c   Ietta, F ^a   Muscettola, M ^d   Carlucci, F ^a   Maioli, E ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c Kyung Hee University   (South Korea)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

AMPK; Autophagy; MTOR; Raptor; Rottlerin

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; PROTEIN KINASE C DELTA; ROTTLERIN; SMALL INTERFERING RNA; SOMATOMEDIN C; ACETOPHENONE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZOPYRAN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MTOR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; PRKCD PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ARTICLE; AUTOPHAGY; BREAST CANCER CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; OXIDATIVE PHOSPHORYLATION UNCOUPLING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETIC TRANSFECTION; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TIME;

RAPTORES;

ACETOPHENONES; ADENOCARCINOMA; AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; AUTOPHAGY; BENZOPYRANS; BREAST NEOPLASMS; FEMALE; HUMANS; MCF-7 CELLS; MULTIPROTEIN COMPLEXES; PHOSPHORYLATION; PROTEIN KINASE C-DELTA; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSFECTION;

EID: 84924493432     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.01.040     Document Type: Article

References (49)

1. Pyo J.O., Nah J., Jung Y.K. Molecules and their functions in autophagy. Exp. Mol. Med 2012, 44:73-80.
2. Wilkinson S., Ryan K.M. Autophagy: an adaptable modifier of tumourigenesis. Curr. Opin. Genet. Dev 2010, 20:57-64.
3. Torricelli C., Salvadori S., Valacchi G., Souček K., Slabáková E., Muscettola M., et al. Alternative pathways of cancer cell death by rottlerin: apoptosis versus autophagy. Evid. Based Complement. Alternat. Med 2012, 2012. 980658. 10.1155/2012/980658.
4. Chen Y., Klionsky D.J. The regulation of autophagy - unanswered questions. J. Cell Sci 2011, 124:161-170.
5. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
6. Cheng S.W.Y., Fryer L.G.D., Carling D., Shepherd P.R. Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J. Biol. Chem 2004, 279:15719-15722.
7. Gwinn D.M., Shackelford D.B., Egan D.F., Mihaylova M.M., Mery A., Vasquez D.S., et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 2008, 30:214-226.
8. Pattingre S., Espert L., Biard-Piechaczyk M., Codogno P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie 2008, 90:313-323.
9. Peña-Llopis S., Vega-Rubin-de-Celis S., Schwartz J.C., Wolff N.C., Tran T.A., Zou L., et al. Regulation of TFEB and V-ATPases by mTORC1. EMBO J. 2011, 30:3242-3258.
10. Pattingre S., Tassa A., Qu X., Garuti R., Liang X.H., Mizushima N., et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122:927-939.
11. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat. Cell Biol 2002, 4:648-657.
12. Roux P.P., Ballif B.A., Anjum R., Gygi S.P., Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:13489-13494.
13. Carrière A., Cargnello M., Julien L.A., Gao H., Bonneil E., Thibault P., et al. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr. Biol 2008, 18:269-1277.
14. Torricelli C., Fortino V., Capurro E., Valacchi G., Pacini A., Muscettola M., et al. Rottlerin inhibits the nuclear factor kappaB/cyclin-D1 cascade in MCF-7 breast cancer cells. Life Sci 2008, 82:638-643.
15. Hardie D.G., Carling D., Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell?. Annu. Rev. Biochem 1998, 67:821-855.
16. Soltoff S.P. Evidence that tyrphostins AG10 and AG18 are mitochondrial uncouplers that alter phosphorylation-dependent cell signaling. J. Biol. Chem 2004, 279:10910-10918.
17. Kim J., Guan K.L. Regulation of the autophagy initiating kinase ULK1 by nutrients: roles of mTORC1 and AMPK. Cell Cycle 2011, 10:1337-1338.
18. Egan D., Kim J., Shaw R.J., Guan K.L. The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR. Autophagy 2011, 7:643-644.
19. Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A., Mair W., et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 2011, 331:456-461.
20. Zhao M., Klionsky D.J. AMPK-dependent phosphorylation of ULK1 induces autophagy. Cell Metab 2011, 13:119-120.
21. Tillman D.M., Izeradjene K., Szucs K.S., Douglas L., Houghton J.A. Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res 2003, 63:5118-5125.
22. Song K.S., Kim J.S., Yun E.J., Kim Y.R., Seo K.S., Park J.H., et al. Rottlerin induces autophagy and apoptotic cell death through a PKC-δ-independent pathway in HT1080 human fibrosarcoma cells: the protective role of autophagy in apoptosis. Autophagy 2008, 4:650-658.
23. Maioli E., Torricelli C., Fortino V., Carlucci F., Tommassini V., Pacini A. Critical appraisal of the MTT assay in the presence of rottlerin and uncouplers. Biol. Proced. Online 2009, 1:227-240.
24. Kojima K., Motoshima H., Tsutsumi A., Igata M., Matsumura T., Kondo T., et al. Rottlerin activates AMPK possibly through LKB1 in vascular cells and tissues. Biochem. Biophys. Res. Commun 2008, 376:434-438.
25. Dhruv K., Sharmila S., Rakesh K.S. Rottlerin-induced autophagy leads to the apoptosis in breast cancer stem cells: molecular mechanisms. Mol. Cancer 2013, 12:171. 10.1186/1476-4598-12-171.
26. Bennasser Y., Bahraoui E. HIV-1 Tat protein induces interleukin-10 in human peripheral blood monocytes: involvement of protein kinase C-betaII and -delta. FASEB J. 2002, 16:546-554.
27. Jung S.K., Lee K.W., Byun S., Kang N.J., Lim S.H., Heo Y.S., et al. Myricetin suppresses UVB-induced skin cancer by targeting Fyn. Cancer Res 2008, 68:6021-6029.
28. Carew J.S., Kelly K.R., Nawrocki S.T. Mechanisms of mTOR inhibitor resistance in cancer therapy. Target. Oncol 2011, 6:17-27.
29. Maioli E., Torricelli C., Valacchi G. Rottlerin and cancer: novel evidence and mechanisms. ScientificWorldJournal 2012, 2012. 350826. 10.1100/2012/350826.
30. Kwon K.Y., Viollet B., Yoo O.J. CCCP induces autophagy in an AMPK-independent manner. Biochem. Biophys. Res. Commun 2011, 416:343-348.
31. Peterson R.T., Desai B.N., Hardwick J.S., Schreiber S.L. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycin associated protein. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:4438-4442.
32. De-Xing H., Takuma K. Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modelling. Antioxid. Redox Signal 2010, 13:691-719.
33. Maioli E., Greci L., Soucek K., Hyzdalova M., Pecorelli A., Fortino V., et al. Rottlerin inhibits ROS formation and prevents NFB activation in MCF-7 and HT-29 cells. J. Biomed. Biotechnol 2009, 2009. 742936. 10.1155/2009/742936.
34. Lin C.J., Lin C.Y., Chen Y., Huang S.H., Wang S.M. Rottlerin inhibits migration of follicular thyroid carcinoma cells by PKCdelta-independent destabilization of the focal adhesion complex. J. Cell. Biochem 2010, 110:428-437.
35. Brenner W., Greber I., Gudejko-Thiel J., Beitz S., Schneider E., Walenta S., et al. Migration of renal carcinoma cells is dependent on protein kinase Cδ via β1 integrin and focal adhesion kinase. Int. J. Oncol 2008, 32:1125-1131.
36. Kharait S., Dhir R., Lauffenburger D., Wells A. Protein kinase Cδ signaling downstream of the EGF receptor mediates migration and invasiveness of prostate cancer cells. Biochem. Biophys. Res. Commun 2006, 343:848-856.
37. Valacchi G., Pecorelli A., Sticozzi C., Torricelli C., Muscettola M., Aldinucci C., et al. Rottlerin exhibits antiangiogenic effects in vitro. Chem. Biol. Drug Des 2011, 77:460-467.
38. Lim J.H., Woo S.M., Min K.J., Park E.J., Jang J.H., Seo B.R., et al. Rottlerin induces apoptosis of HT29 colon carcinoma cells through NAG-1 upregulation via an ERK and p38 MAPK-dependent and PKC δ-independent mechanism. Chem. Biol. Interact 2012, 197:1-7.
39. Lim J.H., Park J.W., Kim S.H., Choi Y.H., Choi K.S., Kwon T.K. Rottlerin induces pro-apoptotic endoplasmic reticulum stress through the protein kinase C-delta-independent pathway in human colon cancer cells. Apoptosis 2008, 13:1378-1385.
40. Singh B.N., Kumar D., Shankar S., Srivastava R.K. Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells. Biochem. Pharmacol 2012, 84:1154-1163.
41. Balgi A.D., Fonseca B.D., Donohue E., Tsang T.C., Lajoie P., Proud C.G., et al. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS ONE 2009, 4. e7124. 10.1371/journal.pone.0007124.
42. Dufner A., Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp. Cell Res 1999, 253:100-109.
43. Beevers C.S., Chen L., Liu L., Luo Y., Webster N.J., Huang S. Curcumin disrupts the mammalian target of rapamycin-raptor complex. Cancer Res 2009, 69:1000-1008.
44. Xie H., Zhu F., Huang Z., Lee M.H., Kim D.J., Li X., et al. Identification of mammalian target of rapamycin as a direct target of fenretinide both in vitro and in vivo. Carcinogenesis 2012, 33:1814-1821.
45. Shim J.H., Su Z.Y., Chae J.I., Kim D.J., Zhu F., Ma W.Y., et al. Epigallocatechin gallate suppresses lung cancer cell growth through Ras-GTPase-activating protein SH3 domain-binding protein 1. Cancer Prev. Res. (Phila.) 2010, 5:670-679.
46. Tran P.L., Kim S.A., Choi H.S., Yoon J.H., Ahn S.G. Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo. BMC Cancer 2010, 10:276. 10.1186/1471-2407-10-276.
47. Lee S.J., Langhans S.A. Anaphase-promoting complex/cyclosome protein Cdc27 is a target for curcumin-induced cell cycle arrest and apoptosis. BMC Cancer 2012, 12:44. 10.1186/1471-2407-12-44.
48. Lee E., Son J.E., Byun S., Lee S.J., Kim Y.A., Liu K., et al. CDK2 and mTOR are direct molecular targets of isoangustone A in the suppression of human prostate cancer cell growth. Toxicol. Appl. Pharmacol 2013, 272:12-20.
49. Seon M.R., Park S.Y., Kwon S.J., Lim S.S., Choi H.J., Park H., et al. Hexane/ethanol extract of Glycyrrhiza uralensis and its active compound isoangustone A induce G1 cycle arrest in DU145 human prostate and 4T1 murine mammary cancer cells. J. Nutr. Biochem 2012, 23:85-92.